Year: 2013
Type: review
Abstract: Cancer cell metabolism is characterized by an enhanced uptake and utilization of glucose, a phenomenon known as the Warburg effect. The persistent activation of aerobic glycolysis in cancer cells can be linked to activation of oncogenes or loss of tumor suppressors, thereby fundamentally advancing cancer progression. In this respect, inhibition of glycolytic capacity may contribute to an anticancer effect on malignant cells. Understanding the mechanisms of aerobic glycolysis may present a new basis for cancer treatment. Accordingly, interrupting lactate fermentation and/or other cancer-promoting metabolic sites may provide a promising strategy to halt tumor development. In this review, we will discuss dysregulated and reprogrammed cancer metabolism followed by clinical relevance of the metabolic enzymes, such as hexokinase, phosphofructokinase, pyruvate kinase M2, lactate dehydrogenase, pyruvate dehydrogenase kinase and glutaminase. The proper intervention of these metabolic sites may provide a therapeutic advantage that can help overcome resistance to chemotherapy or radiotherapy. The unique metabolic characteristics of cancer cells can be exploited to develop new therapies that either halt tumor growth directly or prevent the evolution of resistance to other drugs. A team led by Sung Soo Kim of Kyung Hee University in Seoul, Korea, has reviewed the ways in which cellular metabolism is rewired in cancer. Most notably, cancer cells use much more glucose than normal cells for energy production. Mutations in genes that encode metabolic enzymes — including hexokinase, lactate dehydrogenase, glutaminase and others — are often responsible for the altered energy use profile. Many drug development teams are now actively searching for compounds that can inhibit these enzymes. Kim and colleagues note that such agents may work as standalone treatments or to enhance the efficacy of common radio- and chemotherapies.
DOI: 10.1038/emm.2013.85
Authors: Miran Jang, Sung Soo Kim, Jinhwa Lee
Institutions: Kyung Hee University, Dongseo University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,490
Funder: Dongseo University
OpenAlex ID: W2086965865
